Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
|Articles|October 1, 2002
Supplements and Featured Publications
- Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience
- Volume 8
- Issue 15 Suppl
Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors
Advertisement
Articles in this issue
about 24 years ago
Participating Facultyabout 24 years ago
Cardiorenal Differences Among NSAIDs and Coxibs: Real-World ExperienceAdvertisement
Related to this article
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
5